

# CITATION REPORT

List of articles citing

**Systematic review with network meta-analysis: the efficacy of anti-tumour necrosis factor-alpha agents for the treatment of ulcerative colitis**

**DOI: 10.1111/apt.12644**

**Alimentary Pharmacology and Therapeutics, 2014, 39, 660-71**

**Source:** <https://exaly.com/paper-pdf/58917915/citation-report.pdf>

**Version:** 2024-04-25

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
125	Management of inflammatory bowel disease in poor responders to infliximab. <b>2014</b> , 7, 359-67		22
124	Incorporating alternative design clinical trials in network meta-analyses. <b>2015</b> , 7, 29-35		6
123	Letter: biological drugs for inducing remission in ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2014</b> , 39, 1242-4	6.1	2
122	Letter: biological drugs for inducing remission in ulcerative colitis - authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2014</b> , 39, 1244	6.1	
121	Corrigendum. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2014</b> , 39, 1345-1347	6.1	
120	Drug therapies for ulcerative proctitis: systematic review and meta-analysis. <b>2014</b> , 20, 2157-78		13
119	Prior response to infliximab and early serum drug concentrations predict effects of adalimumab in ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2014</b> , 40, 1324-32	6.1	46
118	Systematic review with network meta-analysis: the efficacy of anti-TNF agents for the treatment of Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2014</b> , 39, 1349-62	6.1	122
117	The outcome of infliximab dose doubling in 157 patients with ulcerative colitis after loss of response to infliximab. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2015</b> , 42, 1192-9	6.1	11
116	Pharmacologic therapy for inflammatory bowel disease refractory to steroids. <b>2015</b> , 8, 257-69		17
115	Body fat composition assessment using analytic morphomics predicts infectious complications after bowel resection in Crohn's disease. <b>2015</b> , 21, 1306-13		23
114	Biologics in the management of ulcerative colitis - comparative safety and efficacy of TNF- $\alpha$ antagonists. <b>2015</b> , 11, 63-73		24
113	Characterizing unmet medical need and the potential role of new biologic treatment options in patients with ulcerative colitis and Crohn's disease: a systematic review and clinician surveys. <b>2015</b> , 27, 804-12		28
112	Corrigendum. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2015</b> , 42, 130	6.1	
111	Changes in dynamic contrast-enhanced pharmacokinetic and diffusion-weighted imaging parameters reflect response to anti-TNF therapy in Crohn's disease. <b>2015</b> , 88, 20150547		17
110	Pushing the pedal to the metal: should we accelerate infliximab therapy for patients with severe ulcerative colitis?. <b>2015</b> , 13, 336-8		27
109	Efficacy of tumour necrosis factor antagonists on remission, colectomy and hospitalisations in ulcerative colitis: Meta-analysis of placebo-controlled trials. <b>2015</b> , 47, 356-64		29

108	Positioning Therapy for Ulcerative Colitis. <b>2015</b> , 17, 29	12
107	Clinical outcome of adalimumab therapy in patients with ulcerative colitis previously treated with infliximab: a Danish single-center cohort study. <b>2015</b> , 50, 1018-24	13
106	The economics of adalimumab for ulcerative colitis. <b>2015</b> , 15, 373-7	2
105	Comparative efficacy of golimumab, infliximab, and adalimumab for moderately to severely active ulcerative colitis: a network meta-analysis accounting for differences in trial designs. <b>2015</b> , 9, 693-700	43
104	Efficacy and safety of antiintegrin antibody for inflammatory bowel disease: a systematic review and meta-analysis. <b>2015</b> , 94, e556	24
103	Factors associated with mucosal healing in patients with ulcerative colitis in clinical remission. <b>2015</b> , 21, 840-6	4
102	Biologic agents for IBD: practical insights. <b>2015</b> , 12, 537-45	196
101	Cost per remission and cost per response with infliximab, adalimumab, and golimumab for the treatment of moderately-to-severely active ulcerative colitis. <b>2015</b> , 18, 437-46	11
100	Benefit-risk assessment of golimumab in the treatment of refractory ulcerative colitis. <b>2016</b> , 8, 1-7	3
99	[Golimumab Therapy in Ulcerative Colitis]. <b>2016</b> , 67, 64-73	2
98	Optimizing Treatment with TNF Inhibitors in Inflammatory Bowel Disease by Monitoring Drug Levels and Antidrug Antibodies. <b>2016</b> , 22, 1999-2015	71
97	How Will Evolving Future Therapies and Strategies Change How We Position the Use of Biologics in Moderate to Severely Active Inflammatory Bowel Disease. <b>2016</b> , 22, 998-1009	15
96	Safety Profile of Biologic Drugs in the Therapy of Ulcerative Colitis: A Systematic Review and Network Meta-Analysis. <b>2016</b> , 36, 870-9	17
95	World Gastroenterology Organisation Global Guidelines Inflammatory Bowel Disease: Update August 2015. <b>2016</b> , 50, 803-818	77
94	Comparison of real-world outcomes of adalimumab and infliximab for patients with ulcerative colitis in the United States. <b>2016</b> , 32, 1233-41	20
93	Adalimumab for Moderately to Severely Active Ulcerative Colitis: A Systematic Review and Meta-Analysis. <b>2016</b> , 30, 207-17	8
92	Letter: a prospective real life comparison of the efficacy of adalimumab vs. golimumab in moderate to severe ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2016</b> , 44, 310-1	6.1 7
91	Golimumab for moderately to severely active ulcerative colitis. <b>2016</b> , 9, 1273-82	1

90	Comparative effectiveness and safety of infliximab and adalimumab in patients with ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2016</b> , 43, 994-1003	6.1	26
89	Risk of tuberculosis during infliximab therapy for inflammatory bowel disease, rheumatoid arthritis, and spondyloarthritis: A meta-analysis. <b>2016</b> , 12, 1693-1704		12
88	Comparative Effectiveness of Infliximab and Adalimumab in Crohn's Disease and Ulcerative Colitis. <b>2016</b> , 22, 880-5		29
87	Considerations, challenges and future of anti-TNF therapy in treating inflammatory bowel disease. <b>2016</b> , 16, 1277-90		30
86	Tuberculosis in Anti-Tumour Necrosis Factor-treated Inflammatory Bowel Disease Patients After the Implementation of Preventive Measures: Compliance With Recommendations and Safety of Retreatment. <b>2016</b> , 10, 1186-93		26
85	Approach to Optimize Anti-TNF- $\alpha$ Therapy in Patients With IBD. <b>2016</b> , 14, 83-90		12
84	Golimumab for the treatment of ulcerative colitis. <b>2017</b> , 17, 879-886		21
83	Infliximab vs Adalimumab for UC: Is There A Difference?. <b>2017</b> , 15, 1197-1199		1
82	Evolution of cytokines and inflammatory biomarkers during infliximab induction therapy and the impact of inflammatory burden on primary response in patients with Crohn's disease. <b>2017</b> , 52, 1086-1092		23
81	The Importance of Considering Differences in Study Design in Network Meta-analysis: An Application Using Anti-Tumor Necrosis Factor Drugs for Ulcerative Colitis. <b>2017</b> , 37, 894-904		12
80	Clinical Outcomes Associated with Switching or Discontinuation from Anti-TNF Inhibitors for Nonmedical Reasons. <b>2017</b> , 39, 849-862.e6		23
79	Systematic review with meta-analysis: comparative efficacy of biologics for induction and maintenance of mucosal healing in Crohn's disease and ulcerative colitis controlled trials. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2017</b> , 45, 1291-1302	6.1	160
78	Adalimumab in ulcerative colitis - efficacy, safety and optimization in the era of treat-to target. <b>2017</b> , 17, 613-621		8
77	Pharmacologic therapies for severe steroid refractory hospitalized ulcerative colitis: A network meta-analysis. <b>2017</b> , 32, 1143-1151		10
76	Understanding the Cautions and Contraindications of Immunomodulator and Biologic Therapies for Use in Inflammatory Bowel Disease. <b>2017</b> , 23, 1301-1315		19
75	Prospective comparison of preference and efficacy of adalimumab and infliximab for treating ulcerative colitis naive to antitumor necrosis factor therapy. <b>2017</b> , 96, e7800		8
74	Repeated intensified infliximab induction - results from an 11-year prospective study of ulcerative colitis using a novel treatment algorithm. <b>2017</b> , 29, 98-104		6
73	Systematic review with meta-analysis: comparative efficacy of immunosuppressants and biologics for reducing hospitalisation and surgery in Crohn's disease and ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2017</b> , 45, 3-13	6.1	127

72	Regulatory role of NKG2D+ NK cells in intestinal lamina propria by secreting double-edged Th1 cytokines in ulcerative colitis. <b>2017</b> , 8, 98945-98952		5
71	Response to: 'Simultaneous inhibition of $\alpha/\beta$ integrin and tumor necrosis factor- $\alpha$ in concomitant spondyloarthritis and inflammatory bowel disease' by Richard. <b>2018</b> , 77, e87		1
70	Predicting Corticosteroid-Free Biologic Remission with Vedolizumab in Crohn's Disease. <b>2018</b> , 24, 1185-1192	29	
69	Evidence-based clinical practice guidelines for inflammatory bowel disease. <b>2018</b> , 53, 305-353		249
68	Predicting corticosteroid-free endoscopic remission with vedolizumab in ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2018</b> , 47, 763-772	6.1	48
67	Efficacy and Safety of Adalimumab in Pediatric Ulcerative Colitis: A Real-life Experience from the SIGENP-IBD Registry. <b>2018</b> , 66, 920-925		16
66	The Unfinished Symphony: Golimumab Therapy for Anti-Tumour Necrosis Factor Refractory Crohn's Disease. <b>2018</b> , 12, 458-464		13
65	Toxicity profiles of immunotherapy. <b>2018</b> , 181, 91-100		40
64	Cost-effectiveness of golimumab for the treatment of patients with moderate-to-severe ulcerative colitis in Quebec using a patient level state transition microsimulation. <b>2018</b> , 21, 27-37		1
63	Defining an Optimal Adherence Threshold for Patients Taking Subcutaneous Anti-TNFs for Inflammatory Bowel Diseases. <b>2018</b> , 113, 276-282		22
62	Cessation of Biologics: Can It Be Done?. <b>2018</b> , 141-162		
61	Systematic review with network meta-analysis: first- and second-line pharmacotherapy for moderate-severe ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2018</b> , 47, 162-175	6.1	133
60	Population-based cohort study on comparative effectiveness and safety of biologics in inflammatory bowel disease. <b>2018</b> , 10, 203-213		6
59	A real life comparison of the effectiveness of adalimumab and golimumab in moderate-to-severe ulcerative colitis, supported by propensity score analysis. <b>2018</b> , 50, 1292-1298		11
58	How to predict response to anti-tumour necrosis factor agents in inflammatory bowel disease. <b>2018</b> , 12, 797-810		23
57	Mechanism-Based Treatment Strategies for IBD: Cytokines, Cell Adhesion Molecules, JAK Inhibitors, Gut Flora, and More. <b>2019</b> , 4, 79-96		35
56	Inflammatory Bowel Disease. <b>2019</b> , 373-424		
55	An approach to acute severe ulcerative colitis. <b>2019</b> , 13, 943-955		5

54	Comparison of the Quantum Blue <sup>®</sup> reader Point-of-Care system versus ELISA technique for therapeutic drug monitoring of Infliximab levels. <b>2019</b> , 74, 73-75	3
53	Medical Management of Inflammatory Bowel Disease. <b>2019</b> , 99, 1223-1235	5
52	Engineered and wild-type <i>L. lactis</i> promote anti-inflammatory cytokine signalling in inflammatory bowel disease patient's mucosa. <b>2019</b> , 35, 45	9
51	The Impact of Raising the Bar for Clinical Trials in Ulcerative Colitis. <b>2019</b> , 13, 1217-1226	4
50	Efficacy and safety of biologic agents and tofacitinib in moderate-to-severe ulcerative colitis: A systematic overview of meta-analyses. <b>2019</b> , 7, 1285-1303	14
49	Assessment of the real-world safety profile of vedolizumab using the United States Food and Drug Administration adverse event reporting system. <i>PLoS ONE</i> , <b>2019</b> , 14, e0225572	3-7 8
48	Comparative effectiveness of antitumour necrosis factor agents and vedolizumab in ulcerative colitis. <b>2019</b> , 31, 661-667	7
47	Determination of Serum Infliximab Concentration by Point-of-care Devices in Children With Inflammatory Bowel Disease. <b>2019</b> , 69, 474-479	8
46	ACG Clinical Guideline: Ulcerative Colitis in Adults. <b>2019</b> , 114, 384-413	458
45	Golimumab in inflammatory bowel diseases: present and future scenarios. <b>2019</b> , 12, 1-9	3
44	2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis. <b>2019</b> , 4, 31-58	6
43	The Impact of Inflammatory Bowel Disease in Canada 2018: A Scientific Report from the Canadian Gastro-Intestinal Epidemiology Consortium to Crohn's and Colitis Canada. <b>2019</b> , 2, S1-S5	24
42	Special Article: 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis. <b>2019</b> , 71, 5-32	178
41	Special Article: 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis. <b>2019</b> , 71, 2-29	137
40	Efficacy of Tumor Necrosis Factor Antagonist Treatment in Patients With Refractory Ulcerative Proctitis. <b>2020</b> , 18, 620-627.e1	7
39	Ulcerative Colitis: Current and Emerging Treatment Strategies. <b>2019</b> , 9,	19
38	Anti-tumour necrosis factor- $\alpha$ therapy and recurrent or new primary cancers in patients with inflammatory bowel disease, rheumatoid arthritis, or psoriasis and previous cancer in Denmark: a nationwide, population-based cohort study. <b>2020</b> , 5, 276-284	19
37	Synthesis and anti-inflammatory intestinal activity of new glucocorticoid derivatives. <b>2020</b> , 29, 206-216	1

36	Concomitant 5-Aminosalicylate Therapy in Moderate-to-Severe Ulcerative Colitis Patients Escalated to Infliximab Is Not Beneficial. <b>2021</b> , 66, 3985-3992		0
35	Efficacies of first and second tumor necrosis factor inhibitors in refractory ulcerative colitis patients in real-world practice. <b>2020</b> , 39, 565-575		1
34	Optimizing biologic therapy in IBD: how essential is therapeutic drug monitoring?. <b>2020</b> , 17, 702-710		19
33	Upregulation of microRNA-219-5p relieves ulcerative colitis through balancing the differentiation of Treg/Th17 cells. <b>2020</b> , 32, 813-820		3
32	Sustained Corticosteroid-Free Clinical Remission During Vedolizumab Maintenance Therapy in Patients with Ulcerative Colitis on Stable Concomitant Corticosteroids During Induction Therapy: A Post Hoc Analysis of GEMINI 1. <b>2020</b> , 13, 211-220		1
31	Real-world clinical effectiveness and safety of vedolizumab and anti-tumor necrosis factor alpha treatment in ulcerative colitis and Crohn's disease patients: a German retrospective chart review. <b>2020</b> , 20, 211		6
30	Comparison of Real-World Outcomes of Infliximab versus Adalimumab in Biologic-Naïve Korean Patients with Ulcerative Colitis: A Population-Based Study. <b>2020</b> , 61, 48-55		4
29	Using Healthcare Databases to Replicate Trial Findings for Supplemental Indications: Adalimumab in Patients with Ulcerative Colitis. <b>2020</b> , 108, 874-884		1
28	Histoplasmosis in Inflammatory Bowel Disease with Tumor Necrosis Factor-Alpha Inhibitors: Safe to Continue Biologics?. <b>2021</b> , 66, 190-198		3
27	Comparison of Long-Term Outcomes of Infliximab versus Adalimumab Treatment in Biologic-Naïve Patients with Ulcerative Colitis. <i>Gut and Liver</i> , <b>2021</b> , 15, 232-242	4.8	2
26	Integrating efficacy and safety of vedolizumab compared with other advanced therapies to assess net clinical benefit of ulcerative colitis treatments: a network meta-analysis. <b>2021</b> , 15, 711-722		1
25	A Real-world Retrospective multi-centre cohort study comparing infliximab and adalimumab for the maintenance of remission in ulcerative colitis. <i>GastroHep</i> , <b>2021</b> , 3, 229-235	1	0
24	Resilience Factors in Paediatric Inflammatory Bowel Disease: Health Care Provider, Parent and Youth Perspectives. <i>Journal of Child and Family Studies</i> , <b>2021</b> , 30, 2250-2263	2.3	
23	Infliximab versus Adalimumab: Can We Choose the Right One for the Right Patients with Ulcerative Colitis?. <i>Gut and Liver</i> , <b>2021</b> ,	4.8	
22	Guía de práctica clínica 2021 para el diagnóstico, el tratamiento y el seguimiento de pacientes con espondiloartritis periférica. Asociación Colombiana de Reumatología. <i>Revista Colombiana De Reumatología</i> , <b>2021</b> , 29, 44-44	0.2	
21	Efficacy and safety of fecal transplantation versus targeted therapies in ulcerative colitis: network meta-analysis. <i>Future Microbiology</i> , <b>2021</b> , 16, 1215-1227	2.9	0
20	Real-Life Comparison of Different Anti-TNF Biologic Therapies for Ulcerative Colitis Treatment: A Retrospective Cohort Study. <i>Digestive Diseases</i> , <b>2021</b> , 39, 16-24	3.2	7
19	Corticosteroid Use and Complications in a US Inflammatory Bowel Disease Cohort. <i>PLoS ONE</i> , <b>2016</b> , 11, e0158017	3.7	75

18	Systematic Review with Network Meta-Analysis: Comparative Efficacy of Biologics in the Treatment of Moderately to Severely Active Ulcerative Colitis. <i>PLoS ONE</i> , <b>2016</b> , 11, e0165435	3.7	62
17	Initial experience with golimumab in clinical practice for ulcerative colitis. <i>Revista Espanola De Enfermedades Digestivas</i> , <b>2016</b> , 108, 129-32	0.9	13
16	A medicoeconomic review of early intervention with biologic agents in the treatment of inflammatory bowel diseases. <i>ClinicoEconomics and Outcomes Research</i> , <b>2014</b> , 6, 431-43	1.7	11
15	Real-life outcome of anti-tumor necrosis factor $\alpha$ in the ambulatory treatment of ulcerative colitis. <i>World Journal of Gastroenterology</i> , <b>2015</b> , 21, 3282-90	5.6	15
14	First United Arab Emirates consensus on diagnosis and management of inflammatory bowel diseases: A 2020 Delphi consensus. <i>World Journal of Gastroenterology</i> , <b>2020</b> , 26, 6710-6769	5.6	4
13	Current and emerging biologics for ulcerative colitis. <i>Gut and Liver</i> , <b>2015</b> , 9, 18-27	4.8	66
12	Efficacy and Safety of Long-Term Thiopurine Maintenance Treatment in Japanese Patients With Ulcerative Colitis. <i>Intestinal Research</i> , <b>2015</b> , 13, 250-8	4.1	11
11	Understanding the Role of Adalimumab in the Treatment of Moderately to Severely Active Ulcerative Colitis. <i>Gut and Liver</i> , <b>2016</b> , 10, 162-3	4.8	
10	Anti-TNF Biologic Therapies Other than Infliximab. <b>2017</b> , 401-416		
9	Guía de práctica clínica 2021 para el diagnóstico, el tratamiento y el seguimiento de pacientes con espondiloartritis periférica. Asociación Colombiana de Reumatología. <i>Reumatología Clínica</i> , <b>2021</b> ,	0.9	
8	GB1a Ameliorates Ulcerative Colitis via Regulation of the NF- $\kappa$ B and Nrf2 Signaling Pathways in an Experimental Model. <i>Frontiers in Medicine</i> , <b>2021</b> , 8, 654867	4.9	1
7	Medical Management of Ulcerative Colitis. <b>2022</b> , 765-779		
6	2021 clinical practice guidelines for the diagnosis, treatment, and follow-up of patients with peripheral spondyloarthritis. Colombian Association of Rheumatology.. <i>Reumatología Clínica (English Edition)</i> , <b>2022</b> ,	0.1	
5	2021 clinical practice guidelines for the diagnosis, treatment, and follow-up of patients with peripheral spondyloarthritis. Colombian Association of Rheumatology. <i>Revista Colombiana De Reumatología (English Edition)</i> , <b>2022</b> , 29, 44-56	0.1	
4	Protective Effect of Dietary Polysaccharides from Yellow Passion Fruit Peel on DSS-Induced Colitis in Mice. <b>2022</b> , 2022, 1-15		0
3	Introducing Biosimilars into Current Inflammatory Bowel Disease Treatment Algorithms. 34-41		0
2	Pharmacodynamic mechanisms behind a refractory state in inflammatory bowel disease. <b>2022</b> , 22,		1
1	Intestinal complications in Brazilian patients with ulcerative colitis treated with conventional therapy between 2011 and 2020. 29, 1330-1343		0



